Acquired Hemophilia A During Prasugrel Therapy After Recurrent Acute Coronary Syndrome
Open Access
- 16 April 2026
- journal article
- case report
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (21) , 107840
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Laboratory investigation and clinical management of acquired coagulation factor inhibitors: A joint British Society for Haematology and United Kingdom Haemophilia Centre Doctors' Organisation GuidelineBritish Journal of Haematology, 2025
- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary SyndromesJACC, 2025
- Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working GroupHamostaseologie, 2023
- Drug‐associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance databaseHaemophilia, 2022
- Emicizumab for the treatment of acquired hemophilia ABlood, 2021
- International recommendations on the diagnosis and treatment of acquired hemophilia AHaematologica, 2020
- JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery DiseaseCirculation Journal, 2020
- Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary InterventionCirculation, 2019
- Acquired Hemophilia a may be Associated with Ticagrelor Therapy in a 52-Year-Old Man after a Recent Percutaneous Transluminal Coronary AngioplastyClinical Medicine Insights: Case Reports, 2016
- Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)Journal of Thrombosis and Haemostasis, 2012